Monte Rosa Therapeutics (GLUE) Capital Expenditures (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Capital Expenditures of $2.7 million for Q1 2026, up 800.0% year-over-year from $304000.0 in Q1 2025, and up 1043.45% quarter-over-quarter from -$290000.0 in Q4 2025.
Monte Rosa Therapeutics (GLUE) Capital Expenditures (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Capital Expenditures history runs 7 years deep, the most recent figure standing at $2.7 million for Q1 2026.
- In Q1 2026, Capital Expenditures rose 800.0% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $2.6 million (up 510.33% YoY), while the FY2025 annual figure was $149000.0, up 198.0% from the prior year.
- Capital Expenditures for Q1 2026 stood at $2.7 million, up from -$290000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $17.8 million in Q4 2023, with the low at -$14.4 million in Q3 2023.
- The 5-year median for Capital Expenditures is $983000.0 (2024), against an average of $2.1 million.
- The sharpest annual moves came in 2023 and 2025: Capital Expenditures soared 4391.03% in 2023, then sank 812.53% in 2025.
- Monte Rosa Therapeutics' Capital Expenditures stood at $8.2 million in 2022, then soared by 117.76% to $17.8 million in 2023, then sank by 121.13% to -$3.8 million in 2024, then soared by 92.28% to -$290000.0 in 2025, then surged by 1043.45% to $2.7 million in 2026.
- Business Quant data shows GLUE's Capital Expenditures at $2.7 million in Q1 2026, -$290000.0 in Q4 2025, and -$2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | 3.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.86 Mn |
| Jun 30, 2026 | 3.86 Mn |
| Mar 31, 2026 | 2.74 Mn |
| Mar 31, 2026 | 2.74 Mn |
| Dec 31, 2025 | -290,000.00 |
| Dec 31, 2025 | -290,000.00 |
| Sep 30, 2025 | -2.84 Mn |
| Sep 30, 2025 | -2.84 Mn |
| Jun 30, 2025 | 2.98 Mn |
| Jun 30, 2025 | 2.98 Mn |
| Mar 31, 2025 | 304,000.00 |
| Mar 31, 2025 | 304,000.00 |
| Dec 31, 2024 | -3.76 Mn |
| Dec 31, 2024 | -3.76 Mn |
| Sep 30, 2024 | 399,000.00 |
| Sep 30, 2024 | 399,000.00 |
| Jun 30, 2024 | 2.42 Mn |
| Jun 30, 2024 | 2.42 Mn |
| Mar 31, 2024 | 983,000.00 |
| Mar 31, 2024 | 983,000.00 |